Trial title not recorded
Arsenic Metabolites Measured in Urine
Enrolment: 60 · Results not recorded
Loading the evidence…
Nutraceutical · Betaine-homocysteine S-methyltransferase substrate
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Arsenic Metabolites Measured in Urine
Enrolment: 60 · Results not recorded
Healthy
Enrolment: 8 · Results not recorded
Autoimmune Gastritis
Enrolment: 100 · Results not recorded
Insulin Sensitivity
Enrolment: 23 · Results not recorded
Obesity and Obesity-related Medical Conditions
Enrolment: 34 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Acute liver failure induced by intraperitoneal D-galactosamine (400 mg/kg) plus lipopolysaccharide (100 micrograms/kg); in vitro LPS (1 microgram/ml) stimulation of IEC-18 cells
Betaine pretreatment reduced hepatocyte necrosis and preserved small intestinal villous architecture, lowered serum ALT, AST and total bilirubin, decreased TNF-alpha, IL-1 beta and IL-18, suppressed TLR4 and MyD88 expression, raised (ZO)-1 and occludin expression, reduced intestinal permeability an…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.
Model: Two models: thioacetamide-induced acute hepatotoxicity, and bile duct ligation as a chronic cholestatic liver injury model
Betaine at 10 and 50 mg/kg intraperitoneally reduced histopathological alterations, tissue markers of oxidative stress and serum biomarkers of hepatotoxicity in both the thioacetamide and bile duct ligation models. Betaine also protected hepatocyte mitochondria in both acute and chronic models, sug…
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.